Background: The motto "one size fits all" is clearly inadequate when it comes to drug dosing regimens. Special patient populations, including children, the elderly, and patients with severe co-morbidities, represent vulnerable populations with divergent dosage requirements compared to the general population. Standard pharmaceutical industry practices often exclude special patient populations during the development of new drugs. A lack of evidence-based dosing regimens in these patients increases the risk of treatment failure and toxicity. 

Objectives:

• Investigate the impact of age and severe illness on drug dosing in pediatric and geriatric patients.
• Explore the clinical value of model-driven precision dosing in the clinical setting.

Methods: To minimize the burden on vulnerable patients, innovative research methods, including the use of state-of-the art pharmacometric modelling and microdialysis will be used.